Cargando…

KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients

This study aims to investigate the molecular characteristics of Chinese gastric cancer patients. In our study, the KRAS, BRAF, and PIK3CA mutation status of 485 GC patients were analyzed by Sanger sequencing. Kaplan-Meier analysis was used to plot survival curves according to different genotypes. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Xin-Hui, Chen, Zhi-Ting, Wang, Wen-Hui, Fan, Xin-Juan, Huang, Yan, Wu, Xiao-Bin, Huang, Jing-Lin, Wang, Jing-Xuan, Lin, Han-Jie, Tan, Xiao-Li, Wang, Lei, Wang, Jian-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400811/ https://www.ncbi.nlm.nih.gov/pubmed/30854087 http://dx.doi.org/10.7150/jca.27899

Ejemplares similares

Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer
por: Feng, Juanjuan, et al.
Publicado: (2023)

The Prevalence and Concurrent Pathogenic Mutations of KRAS(G12C) in Northeast Chinese Non-small-cell Lung Cancer Patients
por: Liu, Yan, et al.
Publicado: (2021)

KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples
por: Loong, Herbert Ho-Fung, et al.
Publicado: (2020)

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients
por: Liu, Si-Yang, et al.
Publicado: (2020)

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
por: Qunaj, Lindor, et al.
Publicado: (2023)

KRAS G12D mosaic mutation in a Chinese linear nevus sebaceous syndrome infant
por: Wang, Huijun, et al.
Publicado: (2015)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
por: Mao, Zhongwei, et al.
Publicado: (2022)

Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients
por: Guo, Fang, et al.
Publicado: (2018)

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
por: Bournet, Barbara, et al.
Publicado: (2016)

Prognostic Value of Autophagy, Microsatellite Instability, and KRAS Mutations in Colorectal Cancer
por: Wang, Yuanyuan, et al.
Publicado: (2021)

12-Lipoxygenase promotes epithelial–mesenchymal transition via the Wnt/β-catenin signaling pathway in gastric cancer cells
por: Yang, Xiao-Huang, et al.
Publicado: (2019)

Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRAS(G12C) Inhibitors
por: Luo, Lianxiang, et al.
Publicado: (2022)

CD146 as an adverse prognostic factor in uterine sarcoma
por: Zhou, Yun, et al.
Publicado: (2015)

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
por: Noordhof, Anneloes L., et al.
Publicado: (2023)

The KRAS-G12D mutation induces metabolic vulnerability in B-cell acute lymphoblastic leukemia
por: Xu, Yan, et al.
Publicado: (2022)

Targeting KRAS G12C mutations in colorectal cancer
por: Zhao, Ming-He, et al.
Publicado: (2022)

KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population
por: Hao, Yi-Xin, et al.
Publicado: (2017)

A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRAS(G12C) inhibitors
por: Feng, Siyu, et al.
Publicado: (2022)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients
por: Chen, Jing, et al.
Publicado: (2014)

Targeting KRAS(G12C)-Mutated Advanced Colorectal Cancer: Research and Clinical Developments
por: Ji, Jingran, et al.
Publicado: (2022)

KRAS (G12C) mutation‐induced TOPK overexpression contributes to tumour progression in non‐small cell lung cancer
por: Cai, Chang, et al.
Publicado: (2023)

KRAS Codon 12 and 13 Mutations in Gastric Cancer in the Northeast Iran
por: Ayatollahi, Hossein, et al.
Publicado: (2018)

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases
por: Renaud, Stéphane, et al.
Publicado: (2015)

KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted Therapies
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Osteoblastic Bone Reaction Developing During Treatment With Sintilimab and Bevacizumab in a Patient With KRAS(G12V)-Mutant Lung Adenocarcinoma
por: Chen, Chang Jun, et al.
Publicado: (2023)

Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors
por: Huang, JiaJia, et al.
Publicado: (2010)

Overcoming Resistance to Drugs Targeting KRAS(G12C) Mutation
por: Jiao, Delong, et al.
Publicado: (2020)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
por: Yang, Qiwei, et al.
Publicado: (2018)

AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research
por: Wu, Lei-Lei, et al.
Publicado: (2023)

Covalent inhibitor targets KRas(G12C): A new paradigm for drugging the undruggable and challenges ahead
por: Li, Hui-yu, et al.
Publicado: (2021)

Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS(G12C)
por: Zhuang, Haiming, et al.
Publicado: (2022)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma
por: Yuan, Xiao-Han, et al.
Publicado: (2018)

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
por: Huang, Ching-Wen, et al.
Publicado: (2013)

The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations
por: Zheng, Difan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u3r5naf8ihl9q069g2un4k238o